Marshall Wace
KLDO

Marshall Wace’s Kaleido Biosciences, Inc. Common Stock KLDO Stock Holding History

Marshall Wace’s Portfolio KLDO Stock Details KLDO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-12,356
Closed -$100K – 3409
2021
Q1 		$100K Buy
+12,356
New +$135K ﹤0.01% 2357

Other funds holding KLDO

FP
Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
HP
Harbourvest Partners Boston, Massachusetts $101M AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Marshall Wace's KLDO Position: Q2 2021 in Review

Marshall Wace sold out of Kaleido Biosciences, Inc. Common Stock (KLDO) in Q2 2021, closing a stake of 12,356 shares — an estimated $100K sold.

Marshall Wace first reported a position in KLDO in Q1 2021 and held it in 1 quarter. The position peaked at $100K in Q1 2021. 71 funds tracked by Wall St. Rank hold KLDO as of Q2 2021.

  • Marshall Wace reported no remaining Kaleido Biosciences, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace sold 12,356 Kaleido Biosciences, Inc. Common Stock shares in Q2 2021, an estimated $100K.
  • Marshall Wace first reported a position in Kaleido Biosciences, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • Marshall Wace's Kaleido Biosciences, Inc. Common Stock position peaked at $100K in Q1 2021.
  • 71 funds tracked by Wall St. Rank held Kaleido Biosciences, Inc. Common Stock as of Q2 2021.

Based on Marshall Wace's 13F filing for Q2 2021, filed 13 Aug 2021.